(MENAFN- GlobeNewsWire - Nasdaq) Ongoing R&D activities, which are leading to the development of new data, test results, and scientific breakthroughs, are driving market expansion.New York, USA, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Market Overview
The market for CAR-T cell therapy is poised to exhibit a robust CAGR of 36.8% during 2025–2034. The CAR-T cell therapy market size was valued at USD 7.31 billion in 2024 and is projected to grow to USD 188.84 billion by 2034.
Market Introduction
Chimeric antigen receptor (CAR) T-cell therapy is a type of cancer immunotherapy treatment that relies on the patient's immune system for attacking cancer cells. It involves the insertion of a tube into the vein of the patient's arm to remove blood and separate the T cells from the rest of the blood. Then, the T cells are infused with a gene for CAR in a laboratory setting. After growing in large numbers, the CAR T cells are infused back into the individual's body. The therapy is advised for fighting against certain cancer types, including lymphoma, leukemia, and multiple myeloma. Research indicates that CAR-T cell therapy can be very effective, even when other treatment options have stopped working.
Download Free Sample PDF Copy of Report:
CAR-T Cell Therapy Market Report Scope
| Report Attributes | Details |
| Market Size Value in 2024 | USD 7.31 billion |
| Market Size Value in 2025 | USD 11.25 billion |
| Revenue Forecast by 2034 | USD 188.84 billion |
| CAGR | 36.8 % from 2025 to 2034 |
| Base Year | 2024 |
| Historical Data | 2020–2023 |
| Forecast Period | 2025–2034 |
Market Key Players
The top market participants are focusing heavily on R&D to improve their product offerings. Also, they are undertaking several strategic initiatives to expand their global footprint. A few of the CAR-T cell therapy market market key players are:
Bluebird Bio Celgene Corporation Gilead Sciences Pfizer Inc. Merck Amgen Intellia Therapeutics Novartis Caribou Biosciences Celyad Nanjing Legend Biotechnology Co., Ltd. Johnson & Johnson Sangamo Therapeutics, Inc.
Growth Drivers and Opportunities
Drivers:
Growing Prevalence of Diffuse Large B-Cell Lymphoma : Diffuse large B-cell lymphoma (DLBCL) often doesn't respond to standard treatments such as monoclonal antibody therapies and chemotherapy. CAR-T cell therapy, which involves modifying a patient's T cells for targeting and destroying cancer cells specifically, has shown high efficacy in DLBCL cases, impacting the CAR-T cell therapy market demand favorably.
Rising Potential Applications in Solid Tumors: Solid tumors such as glioblastoma, lung cancer, and pancreatic cancer account for the majority of cancer cases across the globe. These tumors have limited treatment options, especially in advanced stages. Advances in CAR-T cells to overcome challenges associated with conventional treatment options for solid tumors have shown promising preclinical and clinical results.
Opportunities:
Increasing Expansion Activities : The top market participants are focusing on expansion activities to secure commercial access in regional markets and gain access to treatment centers. These activities are anticipated to boost the CAR-T cell therapy expansion and demand in the upcoming years.
Request For Discount on This Report Before Purchase:
Regional Overview
The CAR-T cell therapy market report offers market insights into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America dominated the market with a 47% share of the market revenue in 2024. The regional market dominance is primarily fueled by the presence of advanced healthcare infrastructure, a high prevalence of hematologic malignancies, and significant research and development investments. Besides, the early adoption of innovative therapies and the presence of a favorable regulatory environment further contribute to market growth in the region.
The Europe CAR-T cell therapy market is anticipated to register a CAGR of 33.2% from 2025 to 2034. The increased focus on expanding access to advanced therapies, along with the rising prevalence of relapsed or refractory hematologic cancers, contribute to the robust growth of the market in Europe.
Inquire More About This Report Before Purchase:
CAR-T Cell Therapy Market Segmentation
By Indication Outlook
DLBCL (Diffuse large B-cell lymphoma) ALL (Acute Lymphoblastic Leukemia) CLL (Chronic Lymphocytic Leukemia) MM (Multiple Myeloma) FL (Follicular Lymphoma) Mastozytosis Myeloid Fibrosis MLL (Mixed Lineage Leukemia) Thymic Cancer Glioblastoma AML (Acute Myeloid Leukemia) Other
By Target Antigen Outlook
CD19/CD22 BCMA (B-Cell Maturation Antigen) Others
By Regional Outlook
North America Europe Germany France UK Italy Spain Netherlands Russia Rest of Europe
Asia Pacific China Japan India Malaysia South Korea Indonesia Australia Vietnam Rest of Asia Pacific
Middle East & Africa Saudi Arabia UAE Israel South Africa Rest of Middle East & Africa
Latin America Mexico Brazil Argentina Rest of Latin America
More Trending Latest Reports by Polaris Market Research:
Railing Market Trends
Oxygen Free Copper Market Size
Breast Cancer Liquid Biopsy Market Share
Digital X-Ray Market Opportunities
Drug Device Combination Products Market Trends
Sports Medicine Market Opportunities
About Polaris Market Research & Consulting, Inc:
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR's clientele spread across different enterprises. We at Polaris are obliged to serve PMR's diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR's customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR's customers.
Contact:
Likhil G
8 The Green Ste 19824,
Dover, DE 19901,
United States
Phone: +1-929 297-9727
Email: ...
Web:
Follow Us: LinkedIn | Twitter
MENAFN19122024004107003653ID1109011131
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.